Agomelatine in the Treatment of Fibromyalgia

Bruno, Antonio; Micò, Umberto; Lorusso, Simona; Cogliandro, Nadia; Pandolfo, Gianluca; Caminiti, Maurizio; Zoccali, Rocco Antonio; Muscatello, Maria Rosaria Anna

doi:10.1097/jcp.0b013e31829057ae

Cited by 20 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an uncontrolled study, agomelatine was administered at a dose of 25 mg to 15 'drug-free' female FMS patients for a period of 12 weeks [75]. Treatment with agomelatine significantly improved depression, anxiety and pain but did not have a significant effect on executive function.…”

Section: • • Melatonin and Related Agentsmentioning

confidence: 99%

Fibromyalgia Syndrome: Novel Therapeutic Targets

Ablin

Haüser

2016

Pain Manag.

View full text Add to dashboard Cite

Fibromyalgia syndrome (FMS) is a chronic disorder characterized by widespread pain and tenderness, accompanied by disturbed sleep, chronic fatigue and multiple additional functional symptoms. FMS continues to pose an unmet need regarding pharmacological treatment and many patients fail to achieve sufficient relief from existing treatments. As FMS is considered to be a condition in which pain amplification occurs within the CNS, therapeutic interventions, both pharmacological and otherwise, have revolved around attempts to influence pain processing in the CNS. In the current review, we present an update on novel targets in the search for effective treatment of FMS.

show abstract

Section: • • Melatonin and Related Agentsmentioning

confidence: 99%

Fibromyalgia Syndrome: Novel Therapeutic Targets

Ablin

Haüser

2016

Pain Manag.

View full text Add to dashboard Cite

show abstract

“…Bruno et al [37] examined the efficacy and tolerability of agomelatine (25 mg) in the treatment of fibromyalgia in a twelve-week, open-label study. Liver function tests were measured at inclusion and upon completion of the study.…”

Section: Reviewmentioning

confidence: 99%

A systematic review of agomelatine-induced liver injury

Freiesleben

Furczyk

2015

J Mol Psychiatr

View full text Add to dashboard Cite

Agomelatine is an antidepressant with a unique mechanism of action. Since its marketing in 2009, concerns have been raised regarding its potential to induce liver injury. The authors therefore address the need to comprehensively evaluate the potential risk posed by agomelatine of inducing liver injury by reviewing data from published and unpublished clinical trials in both the pre- and postmarketing settings, as well as data from non-interventional studies, pharmacovigilance database reviews and one case report. Recommendations for clinicians are also provided.In this review, agomelatine was found to be associated with higher rates of liver injury than both placebo and the four active comparator antidepressants used in the clinical trials for agomelatine, with rates as high as 4.6% for agomelatine compared to 2.1% for placebo, 1.4% for escitalopram, 0.6% for paroxetine, 0.4% for fluoxetine, and 0% for sertraline. The review also provides evidence for the existence of a positive relationship between agomelatine dose and liver injury. Furthermore, rates of liver injury were found to be lower in non-interventional studies. Findings from pharmacovigilance database reviews and one case report also highlight the risk of agomelatine-induced liver injury.As agomelatine does pose a risk of liver injury, clinicians must carefully monitor liver function throughout treatment. However, agomelatine’s unique mechanism of action and favourable safety profile render it a valuable treatment option.A quantitative analysis of agomelatine-induced liver injury is lacking in the literature and would be welcomed.

show abstract

“…According to Velly et al [16], there is a correlation between fibromyalgia, depression and TMJ disorders. According to them, fibromyalgia pain should have a central role and could be considered when evaluating a treatment for TMJ disorders [35]. Hoffmann et al [17] evaluated comorbidities associated with TMJD.…”

Section: Summary Of Evidencementioning

confidence: 99%

Oral Health and Fibromyalgia Syndrome: A Systemic Review

Stefano

Bruno

Muscatello

et al. 2020

JFMK

Self Cite

View full text Add to dashboard Cite

Fibromyalgia is a syndrome currently considered idiopathic and multifactorial rheumatic that causes an increase in muscle tension and is characterized by muscle pain and chronic fibrous tissues—widespread, fluctuating and migrating—associated with stiffness, asthenia, cognitive disorders, insomnia or sleep disorders, alterations in sensitivity to stimuli. In affected patients, there may be anxiety or depressive disorder development. The aim of this study is, with the help of an interdisciplinary team, to evaluate the correlations between this syndrome and oral health. A literature review was conducted, analyzing the most common scientific databases, more than 200 studies were obtained. Subsequently to the application of filters and revision by the authors, only 18 articles were considered eligible for this review. From the results, it is clear that the correlations between fibromyalgia and oral health mainly concern pain in the oro-maxillofacial district, especially in the temporomandibular joint. This certainly could help for faster diagnosis of the syndrome, which is currently difficult to identify.

show abstract

Agomelatine in the Treatment of Fibromyalgia

Cited by 20 publications

References 31 publications

Fibromyalgia Syndrome: Novel Therapeutic Targets

Fibromyalgia Syndrome: Novel Therapeutic Targets

A systematic review of agomelatine-induced liver injury

Oral Health and Fibromyalgia Syndrome: A Systemic Review

Contact Info

Product

Resources

About